Concepedia

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

Yuqin Song, Luis Malpica, Qingqing Cai, Weili Zhao, Keshu Zhou, Jianqiu Wu, Huilai Zhang, Neha Mehta–Shah, Kaiyang Ding, Yao Liu,

The Lancet Oncology · 2023 · 55 citations · 20 references

DOI

Concepts

References

20

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington et al. · Journal of Clinical Oncology · 2014 · 5.6K citations · Full text

, , +17

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

Journal of Clinical Oncology · 2008 · 2.1K citations

, , +14

Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis

Hans Neubauer, Ana Cumano, Mathias Müller et al. · Cell · 1998 · 915 citations · Full text

, , +10

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Alfonso Quintás‐Cardama, Kris Vaddi, Phillip Liu et al. · Blood · 2010 · 827 citations

, , +11

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

, , +12